Search Results

There are 1758 results for: content related to: The Value Proposition of Molecular Medicine

  1. You have free access to this content
    Sipuleucel-T (Provenge®) for castration-resistant prostate cancer

    BJU International

    Volume 110, Issue 2b, July 2012, Pages: E99–E104, Giuseppe Di Lorenzo, Matteo Ferro and Carlo Buonerba

    Version of Record online : 16 DEC 2011, DOI: 10.1111/j.1464-410X.2011.10790.x

  2. Cancer Immunotherapy: Sipuleucel-T and Beyond

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 8, August 2011, Pages: 813–828, Dr. Aimee E. Hammerstrom, Dr. Diana H. Cauley, Dr. Bradley J. Atkinson and Dr. Padmanee Sharma

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.8.813

  3. You have free access to this content
    Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

    Cancer

    Volume 115, Issue 16, 15 August 2009, Pages: 3670–3679, Celestia S. Higano, Paul F. Schellhammer, Eric J. Small, Patrick A. Burch, John Nemunaitis, Lianng Yuh, Nicole Provost and Mark W. Frohlich

    Version of Record online : 17 JUN 2009, DOI: 10.1002/cncr.24429

  4. You have free access to this content
    Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)

    BJU International

    Volume 110, Issue 3, August 2012, Pages: 328–335, A. Oliver Sartor and John M. Fitzpatrick

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1464-410X.2011.10818.x

  5. You have free access to this content
    New developments in castrate-resistant prostate cancer

    BJU International

    Volume 109, Issue s6, June 2012, Pages: 22–32, N. Shore, M. Mason and Th. M. de Reijke

    Version of Record online : 4 JUN 2012, DOI: 10.1111/j.1464-410X.2012.11217.x

  6. You have free access to this content
    Clinical development of novel therapeutics for castration-resistant prostate cancer

    CA: A Cancer Journal for Clinicians

    Volume 62, Issue 5, September/October 2012, Pages: 299–308, Matthew D. Galsky, Alexander C. Small, Che-kai Tsao and William K. Oh

    Version of Record online : 24 APR 2012, DOI: 10.3322/caac.21141

  7. You have free access to this content
    Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

    BJU International

    Volume 110, Issue 5, September 2012, Pages: 658–667, Heather Payne, Amit Bahl, Malcolm Mason, Janis Troup and Johann De Bono

    Version of Record online : 19 MAR 2012, DOI: 10.1111/j.1464-410X.2011.10886.x

  8. You have free access to this content
    HOW DOES SIPULEUCEL-T ALTER OUR CLINICAL PRACTICE?

    BJU International

    Volume 106, Issue 7, October 2010, Pages: 945–946, Daniel George

    Version of Record online : 14 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09642.x

  9. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials

    BJU International

    Accepted manuscript online: 6 JAN 2017, Michiel H.F. Poorthuis, Robin W.M. Vernooij, R. Jeroen A. van Moorselaar and Theo M. de Reijke

    DOI: 10.1111/bju.13764

  10. You have free access to this content
    Prostate cancer immunology – an update for Urologists

    BJU International

    Volume 107, Issue 7, April 2011, Pages: 1046–1051, Nieroshan Rajarubendra, Nathan Lawrentschuk, Damien M. Bolton, Laurence Klotz and Ian D. Davis

    Version of Record online : 10 NOV 2010, DOI: 10.1111/j.1464-410X.2010.09820.x

  11. You have free access to this content
    Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead

    Cancer

    Volume 118, Issue 10, 15 May 2012, Pages: 2583–2593, Jorge A. Garcia and Brian I. Rini

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26582

  12. You have free access to this content
    Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer

    International Journal of Cancer

    Volume 133, Issue 7, 1 October 2013, Pages: 1743–1750, Ning Shao, Yang Wang, Wen Yu Jiang, Di Qiao, Shi Ge Zhang, Ye Wu, Xiang Xiang Zhang, Jiu Ling Wang, Yi Ding and Ning Han Feng

    Version of Record online : 8 APR 2013, DOI: 10.1002/ijc.28162

  13. You have free access to this content
    Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC)

    BJU International

    Volume 113, Issue 3, March 2014, Pages: 367–375, Cristina Suárez, Rafael Morales-Barrera, Victor Ramos, Isaac Núñez, Claudia Valverde, Jacques Planas, Juan Morote, Xavier Maldonado and Joan Carles

    Version of Record online : 12 APR 2013, DOI: 10.1111/bju.12110

  14. You have free access to this content
    IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

    BJU International

    Volume 107, Issue 5, March 2011, Pages: 697–700, Roger S. Kirby and John M. Fitzpatrick

    Version of Record online : 11 FEB 2011, DOI: 10.1111/j.1464-410X.2010.10027.x

  15. You have free access to this content
    Immunotherapy for prostate cancer: the next step?

    Trends in Urology & Men's Health

    Volume 7, Issue 2, March/April 2016, Pages: 28–32, Hannah Rush, Clare Gilson and Simon Chowdhury

    Version of Record online : 4 APR 2016, DOI: 10.1002/tre.514

  16. You have free access to this content
    New clinical advances in immunotherapy for the treatment of solid tumours

    Immunology

    Volume 145, Issue 2, June 2015, Pages: 182–201, Valentina A. Zavala and Alexis M. Kalergis

    Version of Record online : 30 MAR 2015, DOI: 10.1111/imm.12459

  17. You have free access to this content
    A pharmacologic perspective on newly emerging T-cell manipulation technologies

    British Journal of Clinical Pharmacology

    Volume 76, Issue 2, August 2013, Pages: 173–187, Dominic Smethurst

    Version of Record online : 23 JUL 2013, DOI: 10.1111/j.1365-2125.2012.04475.x

  18. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  19. You have free access to this content
    Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 31–42, Phillip PARENTE, Francis PARNIS and Howard GURNEY

    Version of Record online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2011.01506.x

  20. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376